Table 3.
Multivariate Analysis for aGvHD, OS, RFS, and NRM.
| Outcomes | Multivariate analysis | ||
|---|---|---|---|
| Hazard ratio | 95% CI | P value | |
| Grade II-IV aGvHD | |||
| ATG/PTCy vs ATG | 0.357 | 0.128–0.996 | 0.049 |
| Grade III-IV aGvHD | |||
| ATG/PTCy vs ATG | 0.190 | 0.037–0.972 | 0.046 |
| OS | |||
| ECOG | 6.376 | 1.908–21.310 | 0.003 |
| R-DRI | |||
| High risk vs Low/intermediate risk | 7.498 | 1.448–38.828 | 0.016 |
| Grade III-IV aGvHD vs grade 0-I aGvHD | 12.492 | 1.261–123.746 | 0.031 |
| RFS | |||
| ECOG | 5.393 | 2.323–12.518 | <0.001 |
| R-DRI | |||
| High risk vs Low/intermediate risk | 6.738 | 1.643–27.641 | 0.008 |
| Grade III-IV aGvHD vs grade 0-I aGvHD | 14.132 | 1.422–140.442 | 0.024 |
| NRM | |||
| ECOG | 15.664 | 1.904–128.839 | 0.010 |
| R-DRI | |||
| High risk vs Low/intermediate risk | 12.826 | 1.174–140.162 | 0.037 |
| Grade III-IV aGvHD vs grade 0-I aGvHD | 60.148 | 1.678–2156.401 | 0.025 |
aGvHD: acute graft-versus-host disease; OS: overall survival; RFS: relapse-free survival: NRM: non-relapse mortality; ATG: antithymocyte globulin; PTCy: posttransplant cyclophosphamid; ECOG: Eastern Cooperative Oncology Group score standard; R-DRI: revised disease risk index.